Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Male and Female Subjects With Schizophrenia
Status:
Completed
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
This is a study designed to evaluate the safety, tolerability, and PK of SEP-363856 and its
metabolite SEP-363854 in male and female subjects with schizophrenia.